Palladium-mediated cross-coupling reactions are attractive organometallic transformations for the generation of C--C, C--N, C--O, and C--S bonds. Despite being widely employed in small-scale syntheses, cross-coupling reactions have not found important industrial applications because until recently, only reactive aryl bromides and iodides could be used as substrates. These substrates are generally more expensive and less widely available than their chloride counterparts. Over the past few years, new catalytic systems with the ability to activate unreactive and sterically hindered aryl chlorides have been developed. The new catalysts are based on palladium complexes that contain electron-rich and bulky phosphine or carbene ligands. The enhanced reactivity observed with these new systems has been attributed to the formation of unsaturated and reactive [PdL] species which can readily undergo oxidative addition reactions with ArX to yield [Pd(Ar)X(L)].
The synthesis and pharmacological activity of a new series of 1-arylpyrazoles as potent σ(1) receptor (σ(1)R) antagonists are reported. The new compounds were evaluated in vitro in human σ(1)R and guinea pig σ(2) receptor (σ(2)R) binding assays. The nature of the pyrazole substituents was crucial for activity, and a basic amine was shown to be necessary, in accordance with known receptor pharmacophores. A wide variety of amines and spacer lengths between the amino and pyrazole groups were tolerated, but only the ethylenoxy spacer and small cyclic amines provided compounds with sufficient selectivity for σ(1)R vs σ(2)R. The most selective compounds were further profiled, and compound 28, 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862), which showed high activity in the mouse capsaicin model of neurogenic pain, emerged as the most interesting candidate. In addition, compound 28 exerted dose-dependent antinociceptive effects in several neuropathic pain models. This, together with its good physicochemical, safety, and ADME properties, led compound 28 to be selected as clinical candidate.
A series of new palladium dinuclear species with general formula [Pd2X(mu-X)[mu-P(t)Bu2(Bph-R)]] (X = Cl, Br; Bph = biphenyl; R = H, Me, NMe2) have been prepared. The two palladium centers in these species are bridged by one of the aromatic rings of the biphenyl group present in the corresponding phosphine. The X-ray crystal structure of one of these complexes has been obtained, providing a clear picture of the bonding pattern. The stability of these dimers in solution is shown to be highly dependent on the nature of the phosphine R group and also on the bridging halide. When R = NMe2, the dimers dissociate, yielding the palladium(II) compounds PdX2[P(t)Bu2(BPh-NMe2)] (X = Cl, Br), and the X-ray crystal structure of one of them (X = Br) has shown that the biphenyl group from the phosphine interacts directly with the metal center. This interaction seems to play an important role in stabilizing the otherwise coordinatively unsaturated palladium(II) complex. In contrast, when R = H or Me, the analogous monomeric palladium(II) complexes are unstable and undergo cyclometalation to generate a palladium(II) dinuclear species in which each of the two phosphines cyclometalates with the palladium centers forming a strained four-membered ring. In addition to their unusual structures, these aryl-bridged dimers have also proven to be excellent precatalysts for the amination of aryl chlorides. To rationalize some of the experimental results, a detailed DFT computational study has been carried out and is presented herein.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.